Literature DB >> 8568827

Synthesis and biological activity of folic acid and methotrexate analogues containing L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid.

B P Hart1, W H Haile, N J Licato, W E Bolanowska, J J McGuire, J K Coward.   

Abstract

The stereospecific syntheses of L-threo-gamma-fluoromethotrexate (1t) and L-threo-gamma-fluorofolic acid (3t) are reported. Compounds 1t and 3t have no substrate activity with folylpoly-gamma-glutamate synthetase isolated from CCRF-CEM human leukemia cells, and compound 1t inhibits human dihydrofolate reductase at similar levels as methotrexate. The synthesis of DL-3,3-difluoroglutamic acid (6) and its incorporation into DL-beta,beta-difluorofolic acid (4) are also reported. Compound 4 acts as a better substrate for human CCRF-CEM folylpoly-gamma-glutamate synthetase than folic acid (V/K = ca. 7-fold greater). Thus, replacement of the glutamate moiety of methotrexate and folic acid with 4-fluoroglutamic acid and 3,3-difluoroglutamic acid results in folates and antifolates with altered polyglutamylation activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568827     DOI: 10.1021/jm950515e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

Review 1.  Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy.

Authors:  J J McGuire; T Tsukamoto; B P Hart; J K Coward; T I Kalman; J Galivan
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  The glutamate uptake system in presynaptic vesicles: further characterization of structural requirements for inhibitors and substrates.

Authors:  Harry C Winter; Tetsufumi Ueda
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.